What is Transomic Technologies?
Transomic Technologies is a key player in the life sciences industry, providing researchers with an extensive portfolio of lentiviral-based functional genomics tools. Leveraging cutting-edge technologies like CRISPR-Cas9, the company empowers discovery research. Transomic also engages in custom service projects for major pharmaceutical entities, offering solutions ranging from knockout cell lines to sophisticated CRISPR screening assays, thereby accelerating therapeutic development and understanding of biological mechanisms.
How much funding has Transomic Technologies raised?
Transomic Technologies has raised a total of $375K across 1 funding round:
Private Equity
$375K
Private Equity (2022): $375K with participation from Immunotherapy
Key Investors in Transomic Technologies
Immunotherapy
Imunon is a clinical-stage biotechnology company focused on developing innovative DNA-based immunotherapies and vaccines that work in harmony with the bodys immune system. The company leverages proprietary non-viral nucleic acid delivery platforms to create treatments for challenging cancers and infectious diseases, with a strong emphasis on harnessing natural biological mechanisms to generate durable therapeutic responses. Through its integrated research, development, and manufacturing capabilities, Imunon advances novel immunology-driven medicines designed to address unmet medical needs and improve patient outcomes across a broad range of serious health conditions.
What's next for Transomic Technologies?
With its substantial late-stage funding, Transomic Technologies is poised for significant expansion and further innovation in functional genomics. The strategic investment signals confidence from backers in the company's trajectory and its potential to drive advancements in drug discovery and development. Future efforts will likely focus on scaling its proprietary technologies, expanding its service offerings to pharmaceutical partners, and potentially exploring new applications for its CRISPR-based tools in complex disease research. This capital infusion is expected to accelerate the translation of its research tools into tangible clinical and commercial impacts.
See full Transomic Technologies company page
